TITLE:
      Multicenter Trial of Prednisone in Alzheimer's Disease
SUMMARY:
      This is a randomized placebo controlled, double blind study. Patients who meet eligibility
      criteria and decide to participate in the study will be randomly assigned to receive either
      drug treatment or a placebo. Neither the patients nor the participating investigators will
      know who is receiving the drugs and who is receiving the placebo. Participation involves 15
      outpatient clinic visits over a 68 week period. Patients take study medication at varying
      doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.
ELIGIBILITY CRITERIA:
      Inclusion Criteria:

          -  Patients with Alzheimer's disease who are in stable medical condition

        Exclusion Criteria:

          -  Patients with diabetes or severe osteoporosis
